Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

DERM

Journey Medical Corp

May 03 • 04:00PM ET

3.69

Dollar change +0.06
Percentage change 1.65	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC SQLV

Index	-	P/E	-	EPS (ttm)	-0.35	Insider Own	66.61%	Shs Outstand	13.32M	Perf Week	8.53%
Market Cap	73.69M	Forward P/E	-	EPS next Y	-0.20	Insider Trans	0.48%	Shs Float	6.96M	Perf Month	-15.37%
Income	-3.85M	PEG	-	EPS next Q	-0.23	Inst Own	6.71%	Short Float	3.38%	Perf Quarter	-23.44%
Sales	79.18M	P/S	0.93	EPS this Y	-252.38%	Inst Trans	6.31%	Short Ratio	1.51	Perf Half Y	6.96%
Book/sh	1.05	P/B	3.50	EPS next Y	72.97%	ROA	-4.23%	Short Interest	0.24M	Perf Year	156.25%
Cash/sh	1.37	P/C	2.69	EPS next 5Y	-	ROE	-20.64%	52W Range	1.02 - 8.11	Perf YTD	-35.94%
Dividend Est.	-	P/FCF	14.06	EPS past 5Y	-	ROI	-11.01%	52W High	-54.50%	Beta	0.78
Dividend TTM	-	Quick Ratio	1.10	Sales past 5Y	23.37%	Gross Margin	66.33%	52W Low	261.76%	ATR (14)	0.34
Dividend Ex-Date	-	Current Ratio	1.35	EPS Y/Y TTM	86.16%	Oper. Margin	1.98%	RSI (14)	50.13	Volatility	8.57% 9.71%
Employees	58	Debt/Eq	0.87	Sales Y/Y TTM	7.48%	Profit Margin	-4.87%	Recom	1.00	Target Price	8.25
Option/Short	No / Yes	LT Debt/Eq	0.72	EPS Q/Q	81.52%	Payout	-	Rel Volume	0.33	Prev Close	3.63
Sales Surprise	2.05%	EPS Surprise	-594.12%	Sales Q/Q	-4.44%	Earnings	Mar 21 AMC	Avg Volume	155.89K	Price	3.69
SMA20	-1.84%	SMA50	-0.04%	SMA200	-2.02%	Trades		Volume	51,784	Change	1.65%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-07-21	Initiated	B. Riley Securities	Buy	$14

May-01-24 04:01PM	Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer (GlobeNewswire)
Apr-29-24 09:00AM	Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV (ACCESSWIRE)
Apr-25-24 08:30AM	Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024 (GlobeNewswire)
Mar-28-24 04:05PM	Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire) -5.40%
Mar-25-24 07:01PM	Director Justin Smith Acquires 30,000 Shares of Journey Medical Corp (DERM) (GuruFocus.com) -11.52%
06:01AM	Loading…
Mar-22-24 06:01AM	Q4 2023 Journey Medical Corp Earnings Call (Thomson Reuters StreetEvents) -13.61%
Mar-21-24 09:53PM	DERM Stock Earnings: Journey Medical Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
04:01PM	Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-19-24 08:49AM	Journey Medical (DERM) Up as FDA Accepts Skin Disease Drug NDA (Zacks)
Mar-18-24 08:30AM	Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea (GlobeNewswire) +10.00%
Mar-15-24 08:30AM	Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024 (GlobeNewswire)
Mar-13-24 08:30AM	Journey Medical Corporation to Participate in the 36th Annual ROTH Conference (GlobeNewswire)
Mar-11-24 08:30AM	Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting (GlobeNewswire)
Feb-26-24 11:35AM	Journey Medical (DERM) to Report Q4 Earnings: What's in the Cards? (Zacks)
Jan-05-24 08:30AM	Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea (GlobeNewswire)
04:05PM	Loading…
Jan-02-24 04:05PM	Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million (GlobeNewswire) -5.73%
Dec-27-23 08:50AM	Here's What Could Help Journey Medical Corporation (DERM) Maintain Its Recent Price Strength (Zacks)
Dec-13-23 08:09AM	Is it a Good Idea to Buy Journey Medical (DERM) Stock Now? (Zacks)
Dec-07-23 09:16AM	Journey Medical (DERM) Up on Update for Skin Disease Candidate (Zacks) +9.69%
Dec-06-23 08:00AM	Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea (GlobeNewswire) +6.10%
Nov-30-23 12:00PM	Are You Looking for a Top Momentum Pick? Why Journey Medical Corporation (DERM) is a Great Choice (Zacks) +5.43%
Nov-29-23 08:50AM	What Makes Journey Medical Corporation (DERM) a Good Fit for 'Trend Investing' (Zacks) -25.00%
Nov-14-23 04:10PM	Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-12-23 09:36AM	Journey Medical Corporation (NASDAQ:DERM) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 04:01PM	Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire) +5.54%
Nov-01-23 08:00AM	Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors (GlobeNewswire)
Oct-31-23 08:30AM	Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023 (GlobeNewswire) +5.94%
Oct-20-23 08:30AM	Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn (Minocycline Hydrochloride Extended-Release Tablets, 105 mg) (GlobeNewswire) +8.33%
Sep-09-23 01:04AM	Insider Buying: Journey Medical Corp's President & CEO Claude Maraoui Acquires 26,044 Shares (GuruFocus.com)
Sep-07-23 11:45AM	Journey Medical (DERM) & Maruho Ink Deal for Qbrexza Asia Rights (Zacks)
08:00AM	Loading…
Sep-06-23 08:00AM	Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations (GlobeNewswire) +18.66%
Aug-14-23 04:01PM	Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-08-23 06:05PM	Journey Medical Corporation (DERM) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +12.15%
04:01PM	Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-03-23 05:35PM	Assertio (ASRT) Q2 Earnings Miss Estimates (Zacks)
Aug-02-23 04:01PM	Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023 (GlobeNewswire)
Jul-19-23 08:30AM	Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023 (GlobeNewswire)
Jul-11-23 08:30AM	Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults (GlobeNewswire) -16.90%
Jul-04-23 07:34AM	Journey Medical (DERM) to Post Skin Disease Data, Stock Rises 26% (Zacks)
Jul-03-23 08:00AM	Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of July 10, 2023 (GlobeNewswire) +25.79%
Jun-14-23 12:03PM	Journey Medical (DERM) Up on Rosacea Candidate's Positive Data (Zacks)
Jun-13-23 12:11PM	Why Are Journey Medical Shares Trading Higher Today (Benzinga) +22.16%
08:30AM	Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects (GlobeNewswire)
May-22-23 05:15PM	Journey Medical Corporation (DERM) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-19-23 04:01PM	Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023 (GlobeNewswire) +33.33%
May-15-23 04:01PM	Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire) -9.38%
May-11-23 04:01PM	Journey Medical Corporation Announces Postponement of First Quarter Financial Results Release and Conference Call (GlobeNewswire)
May-04-23 09:00AM	Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 11, 2023 (GlobeNewswire) +7.64%
Apr-19-23 02:22PM	Journey Medical Corporation (NASDAQ:DERM) Looks Inexpensive But Perhaps Not Attractive Enough (Simply Wall St.)
Apr-01-23 09:41PM	Journey Medical Corporation (NASDAQ:DERM) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-30-23 04:10PM	Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire) +10.34%
Mar-29-23 05:15PM	Journey Medical Corporation (DERM) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -6.57%
04:01PM	Journey Medical Corporation Reports Full-Year 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-28-23 05:35PM	Infinity Pharmaceuticals (INFI) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +5.38%
Mar-22-23 09:00AM	Journey Medical Corporation to Announce Year End 2022 Financial Results on March 29, 2023 (GlobeNewswire)
Mar-16-23 08:30AM	Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial (GlobeNewswire)
Mar-07-23 08:30AM	Journey Medical Corporation to Participate in the 35th Annual ROTH Conference (GlobeNewswire)
Jan-20-23 04:01PM	Journey Medical Corporation Appoints Joseph Benesch as Interim Chief Financial Officer (GlobeNewswire) -7.57%
Jan-10-23 08:30AM	Journey Medical Corporation Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea (GlobeNewswire) +15.62%
Dec-20-22 10:02AM	Journey Medical Touts Positive PK Data For Bacterial Infection Candidate (Benzinga) -8.46%
08:30AM	Journey Medical Corporation Announces Positive Comparative Pharmacokinetic (PK) Data for DFD-29 (GlobeNewswire)
Dec-05-22 04:05PM	Journey Medical Corporation to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference (GlobeNewswire) -7.57%
Nov-13-22 07:38AM	Journey Medical Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.)
Nov-10-22 05:25PM	Journey Medical Corporation (DERM) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Journey Medical Corporation Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-03-22 08:52AM	Journey Medical Corporation to Announce Third Quarter 2022 Financial Results on November 10, 2022 (GlobeNewswire)
Oct-04-22 08:30AM	Journey Medical Corporation to Participate in Upcoming October 2022 Investor Conferences (GlobeNewswire)
Aug-30-22 08:30AM	Journey Medical Corporation Announces 50% Enrollment Milestone Achieved in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea (GlobeNewswire)
Aug-12-22 06:14AM	Analysts Have Lowered Expectations For Journey Medical Corporation (NASDAQ:DERM) After Its Latest Results (Simply Wall St.)
Aug-09-22 05:55PM	Journey Medical Corporation (DERM) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Journey Medical Corporation Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-04-22 10:00AM	Molecular Templates Inc. (MTEM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Aug-03-22 08:00AM	Journey Medical Corporation to Announce Second Quarter 2022 Financial Results on August 9, 2022 (GlobeNewswire)
Jul-18-22 07:05AM	Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position (GlobeNewswire)
May-24-22 08:30AM	Journey Medical Corporation Announces Settlement Agreements Pertaining to QBREXZA®, AMZEEQ® and ZILXI® Patent Exclusivity (GlobeNewswire)
May-23-22 08:30AM	Journey Medical Corporation to Present at the B. Riley Securities 22nd Annual Institutional Investor Conference (GlobeNewswire) -10.67%
May-16-22 01:20PM	36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022 (ACCESSWIRE)
08:00AM	Entera Bio Board Member, Miranda Toledano, to Assume Role of Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy (GlobeNewswire)
May-10-22 04:01PM	Journey Medical Corporation Reports First Quarter 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire) -5.35%
May-03-22 04:15PM	Journey Medical Corporation to Announce First Quarter 2022 Financial Results on May 10, 2022 (GlobeNewswire) +5.51%
Apr-15-22 09:55AM	Journey Medical Corporation (DERM) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Apr-04-22 08:30AM	Journey Medical Corporation to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities (GlobeNewswire)
Apr-01-22 08:30AM	Fortress Biotech Announces Virtual Two-Day R&D Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022 (GlobeNewswire)
Mar-23-22 04:01PM	Journey Medical Corporation Reports Full-Year 2021 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-18-22 01:15PM	Journey Medical Corporation to Release Year End 2021 Financial Results and Provide Corporate Update on March 23, 2022 (GlobeNewswire) -12.67%
Mar-17-22 08:30AM	Journey Medical Corporation Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Rosacea (GlobeNewswire)
Mar-09-22 08:30AM	Journey Medical Corporation to Present at the 34th Annual ROTH Conference (GlobeNewswire)
Feb-11-22 08:00AM	QBREXZA® (Rapifort® Wipes 2.5%) Receives Manufacturing and Marketing Approval in Japan Triggering $2.5 Million Milestone Payment to Journey Medical Corporation (GlobeNewswire)
Jan-13-22 08:38AM	VYNE Therapeutics Offloads Its Topical Minocycline Assets To Journey Medical In $450M+ Deal (Benzinga)
07:00AM	VYNE Therapeutics Divests Topical Minocycline Assets (GlobeNewswire)
07:00AM	Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and Molecule Stabilizing Technology (MST) Franchise from VYNE Therapeutics, Inc. (GlobeNewswire)
Dec-27-21 07:15AM	How the stocks of 6 Arizona companies fared after going public in 2021 (American City Business Journals)
Dec-10-21 08:00AM	Journey Medical Corporation Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights (GlobeNewswire) +5.63%
Dec-07-21 04:05PM	Journey Medical Corporation to Present at the Benzinga Global Small Cap Conference (GlobeNewswire)
Nov-29-21 08:00AM	Journey Medical Corporation Introduces Expanded Board of Directors (GlobeNewswire)
Nov-16-21 07:21PM	Journey Medical completes IPO with shares below initial pricing (American City Business Journals) -8.89%
04:01PM	Journey Medical Corporation Announces Closing of Initial Public Offering (GlobeNewswire)
Nov-12-21 07:00AM	Journey Medical Corporation Prices $35.2 Million Initial Public Offering (GlobeNewswire)

Journey Medical Corp. is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its brands include QBREXZA, Accutane, Targadox, AMZEEQ, Ximino, ZILXI, Exelderm, and Luxamend. The company was founded by Claude Maraoui in October 2014 and is headquartered in Scottsdale, AZ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ROSENWALD LINDSAY A MD	Director	Mar 25 '24	Buy	3.04	10,000	30,400	144,245	Mar 27 07:00 AM
Smith Justin Adam	Director	Mar 22 '24	Buy	3.47	30,000	104,100	134,717	Mar 25 04:02 PM
ROSENWALD LINDSAY A MD	Director	Mar 22 '24	Buy	3.40	20,000	68,000	134,245	Mar 25 04:01 PM
Maraoui Claude	President & CEO	Mar 22 '24	Buy	3.48	10,000	34,790	2,163,430	Mar 25 04:03 PM
Benesch Joseph	Interim CFO	Feb 22 '24	Sale	3.75	2,450	9,188	60,710	Feb 23 05:54 PM
Paley Jeffrey	Director	Nov 28 '23	Sale	5.22	1,745	9,109	70,727	Nov 29 04:42 PM
Paley Jeffrey	Director	Nov 08 '23	Sale	3.76	255	959	114,217	Dec 08 05:01 PM
Paley Jeffrey	Director	Nov 07 '23	Sale	3.48	2,245	7,813	114,472	Dec 08 05:01 PM
Smith Justin Adam	Director	Oct 13 '23	Buy	2.98	33,000	98,340	104,717	Oct 17 04:01 PM
Paley Jeffrey	Director	Oct 06 '23	Buy	2.98	15,000	44,700	72,472	Oct 10 04:41 PM
Paley Jeffrey	Director	Sep 21 '23	Buy	2.97	30,000	89,100	57,472	Sep 25 04:01 PM
ROSENWALD LINDSAY A MD	Director	Sep 06 '23	Buy	2.23	100,000	223,000	114,245	Sep 08 01:25 PM
Maraoui Claude	President & CEO	Sep 06 '23	Buy	2.52	26,044	65,631	2,153,430	Sep 08 01:26 PM
Maraoui Claude	President & CEO	Jul 24 '23	Sale	1.76	20,767	36,550	2,127,386	Jul 25 04:05 PM
Benesch Joseph	See Remarks	Jul 24 '23	Sale	1.76	4,072	7,167	63,160	Jul 25 04:05 PM
Maraoui Claude	President & CEO	May 17 '23	Sale	1.34	24,377	32,665	2,148,153	May 18 04:31 PM
Maraoui Claude	President & CEO	May 16 '23	Sale	1.25	20,000	25,000	2,172,530	May 18 04:31 PM

Open in Screener

FBIO

Fortress Biotech Inc

May 03 • 04:00PM ET

1.75

Dollar change -0.05
Percentage change -2.78	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

FBIO Fortress Biotech Inc daily Stock Chart

Held by: VTI VXF FESM

Index	-	P/E	-	EPS (ttm)	-21.66	Insider Own	28.32%	Shs Outstand	15.09M	Perf Week	1.74%
Market Cap	33.65M	Forward P/E	-	EPS next Y	-4.68	Insider Trans	47.93%	Shs Float	13.79M	Perf Month	-6.42%
Income	-66.66M	PEG	-	EPS next Q	-1.73	Inst Own	25.02%	Short Float	13.21%	Perf Quarter	-5.41%
Sales	84.51M	P/S	0.40	EPS this Y	29.40%	Inst Trans	-13.18%	Short Ratio	6.57	Perf Half Y	4.17%
Book/sh	1.49	P/B	1.17	EPS next Y	21.68%	ROA	-26.26%	Short Interest	1.82M	Perf Year	-84.20%
Cash/sh	4.21	P/C	0.42	EPS next 5Y	25.50%	ROE	-188.71%	52W Range	1.24 - 11.53	Perf YTD	-41.86%
Dividend Est.	-	P/FCF	-	EPS past 5Y	22.28%	ROI	-65.56%	52W High	-84.82%	Beta	1.65
Dividend TTM	-	Quick Ratio	1.26	Sales past 5Y	26.66%	Gross Margin	66.41%	52W Low	41.13%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	1.38	EPS Y/Y TTM	-57.11%	Oper. Margin	-164.76%	RSI (14)	45.02	Volatility	6.71% 7.03%
Employees	186	Debt/Eq	3.93	Sales Y/Y TTM	11.58%	Profit Margin	-78.88%	Recom	1.00	Target Price	13.00
Option/Short	Yes / Yes	LT Debt/Eq	3.51	EPS Q/Q	79.56%	Payout	-	Rel Volume	0.64	Prev Close	1.80
Sales Surprise	31.94%	EPS Surprise	52.58%	Sales Q/Q	21.59%	Earnings	Mar 28 AMC	Avg Volume	277.35K	Price	1.75
SMA20	-2.29%	SMA50	-8.36%	SMA200	-48.05%	Trades		Volume	177,764	Change	-2.78%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-15-24	Resumed	ROTH MKM	Buy	$10
Aug-04-22	Initiated	Ladenburg Thalmann	Buy	$6
Oct-02-20	Initiated	The Benchmark Company	Buy	$9
Dec-18-19	Initiated	B. Riley FBR	Buy	$9
Feb-28-18	Initiated	B. Riley FBR, Inc.	Buy	$10
Jul-11-17	Initiated	Rodman & Renshaw	Buy	$11
Mar-22-17	Initiated	JMP Securities	Mkt Outperform
Oct-03-16	Initiated	ROTH Capital	Buy	$9

May-02-24 04:01PM	Mustang Bio Announces Closing of $4 Million Public Offering (GlobeNewswire)
May-01-24 04:01PM	Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer (GlobeNewswire)
Apr-29-24 08:00PM	Mustang Bio Announces Pricing of $4 Million Public Offering (GlobeNewswire)
08:00AM	Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds (GlobeNewswire)
Apr-25-24 08:30AM	Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024 (GlobeNewswire)
07:30AM	Loading…
Apr-24-24 07:30AM	Avenue Therapeutics Announces Reverse Stock Split (GlobeNewswire)
Apr-11-24 12:24PM	3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024 (InvestorPlace)
Mar-28-24 10:53PM	FBIO Stock Earnings: Fortress Biotech Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) -7.83%
04:05PM	Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
09:00AM	Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases (GlobeNewswire)
Mar-25-24 08:30AM	Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024 (GlobeNewswire)
Mar-22-24 08:30AM	Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-21-24 04:01PM	Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-18-24 04:05PM	Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
08:30AM	Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea (GlobeNewswire)
08:00AM	Loading…
08:00AM	Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors (GlobeNewswire)
Mar-15-24 08:30AM	Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024 (GlobeNewswire) +15.18%
08:15AM	Avenue Therapeutics Receives Positive Listing Determination from Nasdaq (GlobeNewswire)
Mar-13-24 08:30AM	Journey Medical Corporation to Participate in the 36th Annual ROTH Conference (GlobeNewswire) -5.45%
Mar-12-24 08:30AM	Fortress Biotech to Participate in 36th Annual ROTH Conference (GlobeNewswire)
Mar-11-24 04:05PM	Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
08:30AM	Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting (GlobeNewswire)
08:00AM	Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting (GlobeNewswire)
Mar-07-24 07:30AM	Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13R 2-targeted CAR T-Cells in High-Grade Glioma (GlobeNewswire) -6.55%
Mar-04-24 08:30AM	Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease (GlobeNewswire) -5.76%
Feb-22-24 08:30AM	Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy (GlobeNewswire)
Feb-02-24 02:40PM	Lindsay Rosenwalds Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries (News Direct) -6.09%
Jan-29-24 08:00AM	Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market (GlobeNewswire)
Jan-11-24 08:30AM	Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference (GlobeNewswire)
08:15AM	Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference (GlobeNewswire)
08:00AM	Loading…
08:00AM	Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference (GlobeNewswire)
Jan-09-24 05:02PM	Insider Buying: President, CEO & Chairman, 10% Owner ROSENWALD LINDSAY A MD Acquires 50,000 ... (GuruFocus.com) -6.19%
Jan-05-24 09:15AM	Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds (GlobeNewswire)
08:30AM	Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea (GlobeNewswire)
Jan-04-24 08:30AM	Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol (GlobeNewswire)
Jan-03-24 04:01PM	Fortress Biotech Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -7.81%
Jan-02-24 04:05PM	Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million (GlobeNewswire) -10.63%
08:30AM	Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) (GlobeNewswire)
Dec-29-23 08:20AM	Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -22.62%
Dec-11-23 08:30AM	Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-06-23 08:30AM	Sentynl Therapeutics Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease from Cyprium Therapeutics (PR Newswire)
08:30AM	Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd. (GlobeNewswire)
08:00AM	Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea (GlobeNewswire)
Dec-05-23 08:30AM	Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance (GlobeNewswire)
Dec-01-23 08:30AM	Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting (GlobeNewswire) +9.60%
Nov-16-23 11:18PM	Insider Buying: President, CEO & Chairman, 10% Owner ROSENWALD LINDSAY A MD Acquires Shares ... (GuruFocus.com)
Nov-14-23 04:29PM	Fortress Biotech: Q3 Earnings Snapshot (Associated Press Finance)
04:10PM	Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:05PM	Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:01PM	Fortress Biotech Announces Closing of $10.0 Million Public Offering (GlobeNewswire)
Nov-13-23 05:00PM	Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:05PM	Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-10-23 08:15AM	Fortress Biotech Announces Pricing of $10.0 Million Public Offering (GlobeNewswire) -37.02%
Nov-09-23 05:05PM	Fortress Biotech Announces Launch of Proposed Public Offering (GlobeNewswire)
Nov-07-23 04:01PM	Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire) -10.50%
Nov-02-23 03:00PM	Avenue Therapeutics Announces Closing of $5.0 Million Public Offering (GlobeNewswire) +15.48%
09:28AM	Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-31-23 09:15AM	Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering (GlobeNewswire) +5.29%
08:30AM	Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023 (GlobeNewswire)
Oct-30-23 02:15PM	Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Oct-26-23 12:30PM	Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
09:00AM	Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13R 2 targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma (GlobeNewswire)
Oct-20-23 08:30AM	Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn (Minocycline Hydrochloride Extended-Release Tablets, 105 mg) (GlobeNewswire) -8.37%
Oct-18-23 08:30AM	Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer (GlobeNewswire) -12.69%
Oct-16-23 09:00AM	Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1 (GlobeNewswire)
Oct-09-23 12:50PM	Fortress Biotech Announces Reverse Stock Split (GlobeNewswire) -12.48%
Oct-05-23 08:30AM	Fortress Biotech to Present at ROTH MKM 2023 Healthcare Opportunities Conference (GlobeNewswire)
Oct-02-23 12:53PM	Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds (GlobeNewswire) +7.85%
Sep-21-23 08:30AM	Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference (GlobeNewswire) -5.93%
Sep-07-23 08:30AM	Fortress Biotech to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
08:15AM	Mustang Bio to Participate in Upcoming September 2023 Investor Conferences (GlobeNewswire)
Sep-06-23 08:30AM	Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) +9.61%
08:00AM	Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations (GlobeNewswire)
Sep-05-23 08:30AM	Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) -10.79%
Aug-16-23 08:00AM	Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy (GlobeNewswire) -9.95%
Aug-14-23 04:19PM	Fortress Biotech: Q2 Earnings Snapshot (AP Finance)
04:15PM	Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:05PM	Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:01PM	Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-10-23 04:15PM	Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-08-23 04:01PM	Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-03-23 08:30AM	Fortress Biotech to Present at the BTIG Virtual Biotechnology Conference 2023 (GlobeNewswire)
08:00AM	Mustang Bio to Participate in Two August 2023 Investor Conferences (GlobeNewswire)
Aug-02-23 04:01PM	Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023 (GlobeNewswire)
Aug-01-23 02:54PM	Insiders Re-Evaluate Their US$3.4m Stock Purchase As Fortress Biotech Falls To US$77m (Simply Wall St.)
08:30AM	Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study (GlobeNewswire)
Jul-31-23 08:30AM	Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences (GlobeNewswire)
08:00AM	Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market (GlobeNewswire)
Jul-27-23 08:30AM	Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) (GlobeNewswire)
07:00AM	Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma (GlobeNewswire)
Jul-25-23 08:30AM	Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol (GlobeNewswire) -16.57%
Jul-19-23 08:30AM	Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023 (GlobeNewswire)
Jul-11-23 08:30AM	Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults (GlobeNewswire)
Jul-06-23 08:00AM	Mustang Bio Announces Participation in Upcoming Scientific Meetings (GlobeNewswire) -5.04%
Jul-05-23 02:31PM	Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shift From Loss To Profit (Simply Wall St.)
Jul-03-23 08:00AM	Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of July 10, 2023 (GlobeNewswire)
Jun-29-23 08:00AM	Urica Therapeutics Announces Topline Data from the Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the United States (GlobeNewswire) +7.55%
Jun-28-23 08:00AM	Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing (GlobeNewswire) -5.69%
Jun-15-23 04:01PM	Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy (GlobeNewswire) +10.55%
08:00AM	Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program (GlobeNewswire)

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Jan 05 '24	Buy	2.38	50,000	118,770	2,863,905	Jan 09 08:15 AM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Nov 14 '23	Buy	1.70	1,567,515	2,664,776	2,597,440	Nov 16 05:50 PM
WEISS MICHAEL S	See Remarks	Nov 14 '23	Buy	1.70	147,058	249,999	1,130,520	Nov 16 05:46 PM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Sep 26 '23	Buy	0.28	100,000	28,330	15,449,091	Sep 27 08:20 AM
Fortress Biotech, Inc.	10% Owner	Sep 08 '23	Buy	0.72	418,410	301,255	1,032,390	Sep 12 09:02 AM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Aug 18 '23	Buy	9.34	10,000	93,400	112,500	Aug 21 08:30 AM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Aug 17 '23	Buy	11.75	10,000	117,500	102,500	Aug 21 08:30 AM

Open in Screener

ATXI

Avenue Therapeutics Inc

May 03 • 04:00PM ET

4.78

Dollar change +0.01
Percentage change 0.21	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

ATXI Avenue Therapeutics Inc daily Stock Chart

Held by: VXF

Index	-	P/E	0.98	EPS (ttm)	4.87	Insider Own	11.82%	Shs Outstand	0.60M	Perf Week	-22.90%
Market Cap	2.87M	Forward P/E	-	EPS next Y	-27.75	Insider Trans	-89.69%	Shs Float	0.53M	Perf Month	-56.64%
Income	-10.38M	PEG	-	EPS next Q	-9.00	Inst Own	2.75%	Short Float	0.49%	Perf Quarter	-54.54%
Sales	0.00M	P/S	-	EPS this Y	58.16%	Inst Trans	-	Short Ratio	0.08	Perf Half Y	-72.29%
Book/sh	4.64	P/B	1.03	EPS next Y	9.76%	ROA	-238.69%	Short Interest	0.00M	Perf Year	-93.69%
Cash/sh	2.97	P/C	1.61	EPS next 5Y	-	ROE	-378.24%	52W Range	4.38 - 93.75	Perf YTD	-60.41%
Dividend Est.	-	P/FCF	-	EPS past 5Y	50.07%	ROI	-655.94%	52W High	-94.90%	Beta	-0.05
Dividend TTM	-	Quick Ratio	1.55	Sales past 5Y	0.00%	Gross Margin	-	52W Low	9.13%	ATR (14)	1.21
Dividend Ex-Date	-	Current Ratio	1.55	EPS Y/Y TTM	28.88%	Oper. Margin	0.00%	RSI (14)	28.49	Volatility	14.10% 14.81%
Employees	3	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	56.25
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	358.44%	Payout	-	Rel Volume	8.31	Prev Close	4.77
Sales Surprise	-	EPS Surprise	950.00%	Sales Q/Q	-	Earnings	Mar 18 AMC	Avg Volume	34.36K	Price	4.78
SMA20	-45.62%	SMA50	-54.81%	SMA200	-83.83%	Trades		Volume	285,527	Change	0.21%

Apr-29-24 08:00AM	Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds (GlobeNewswire) -27.18%
Apr-24-24 07:30AM	Avenue Therapeutics Announces Reverse Stock Split (GlobeNewswire) -29.63%
Mar-25-24 08:30AM	Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024 (GlobeNewswire)
Mar-19-24 06:53AM	ATXI Stock Earnings: Avenue Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
Mar-18-24 04:05PM	Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
08:15AM	Loading…
Mar-15-24 08:15AM	Avenue Therapeutics Receives Positive Listing Determination from Nasdaq (GlobeNewswire)
Mar-11-24 08:00AM	Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting (GlobeNewswire) -15.62%
Feb-22-24 08:30AM	Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy (GlobeNewswire)
Jan-16-24 08:40AM	Sidoti Events, LLC's Virtual January Micro-Cap Conference (ACCESSWIRE) -11.03%
Jan-11-24 08:00AM	Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference (GlobeNewswire)
Jan-05-24 09:15AM	Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds (GlobeNewswire) -44.64%
Jan-04-24 08:30AM	Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol (GlobeNewswire) +95.71%
Jan-02-24 08:30AM	Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) (GlobeNewswire)
Dec-01-23 08:30AM	Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting (GlobeNewswire) -9.43%
Nov-29-23 08:05AM	Why Is Avenue Therapeutics (ATXI) Stock Up 59% Today? (InvestorPlace) -6.99%
04:05PM	Loading…
Nov-13-23 04:05PM	Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire) -12.20%
Nov-02-23 03:00PM	Avenue Therapeutics Announces Closing of $5.0 Million Public Offering (GlobeNewswire)
Oct-31-23 09:15AM	Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering (GlobeNewswire) -33.07%
Sep-05-23 08:30AM	Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) -6.40%
Aug-14-23 04:01PM	Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-10-23 04:15PM	Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-01-23 08:30AM	Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study (GlobeNewswire)
Jul-27-23 08:30AM	Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) (GlobeNewswire)
Jul-25-23 08:30AM	Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol (GlobeNewswire)
May-15-23 04:01PM	Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-12-23 08:30AM	Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Apr-27-23 08:30AM	Avenue Therapeutics to Present at Aegis Capital Virtual Conference (GlobeNewswire)
Apr-17-23 04:01PM	Avenue Therapeutics Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV Tramadol (GlobeNewswire) +5.50%
Mar-30-23 04:10PM	Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:01PM	Avenue Therapeutics Reports Full Year 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:01PM	Loading…
Mar-08-23 04:01PM	Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates (GlobeNewswire)
Mar-02-23 08:00AM	Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular Atrophy (GlobeNewswire)
Jan-31-23 01:30PM	Aegis Capital Corp. Acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATXI) (ACCESSWIRE)
01:09PM	Avenue Therapeutics Announces Closing of $3.25 Million Registered Direct and Private Placement (GlobeNewswire)
Jan-27-23 11:58AM	Avenue Therapeutics Announces $3.25 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules (GlobeNewswire) -10.97%
Nov-10-22 04:10PM	Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire) +12.23%
Nov-08-22 12:26PM	Avenue Therapeutics Buys Baergic Bio, Beefs Up Central Nervous System-Focused Portfolio (Benzinga)
08:30AM	Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A 2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders (GlobeNewswire)
Oct-12-22 10:25AM	Aegis Capital Corp. Acted as Sole Bookrunner on a $12 Million Underwritten Public Offering for Avenue Therapeutics, Inc. (NASDAQ:ATXI) (ACCESSWIRE) -10.56%
Oct-11-22 02:15PM	Avenue Therapeutics Announces Closing of $12 Million Underwritten Public Offering (GlobeNewswire) +10.08%
Oct-06-22 11:00PM	Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering (GlobeNewswire) -25.74%
Oct-03-22 08:00AM	Urica Therapeutics Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer (GlobeNewswire) +14.19%
Sep-23-22 08:51AM	Avenue Therapeutics Announces Reverse Stock Split, Regulatory Update For Lead Its Pain Candidate (Benzinga) -31.82%
Sep-22-22 04:25PM	Avenue Therapeutics Announces Reverse Stock Split and Provides Regulatory Update for IV Tramadol Including Receipt of Type A Meeting Minutes from the FDA (GlobeNewswire) +105.90%
Mar-31-22 07:30AM	Abeona Therapeutics Announces Strategy Update and 2021 Financial Results (GlobeNewswire) -6.29%
Feb-16-22 08:20AM	FDA's AdComm Says Avenue Therapeutics Submitted Insufficient Data On IV Tramadol (Benzinga) -48.69%
Feb-15-22 10:00PM	Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol (GlobeNewswire)
07:05AM	Avenue Therapeutics Stock Trading Halted Today (GlobeNewswire)
Dec-15-21 02:15PM	Aegis Capital Corp. Acted as Sole Bookrunner on a $2 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI) (ACCESSWIRE) -10.77%
12:00PM	Avenue Therapeutics Announces Closing of Public Offering of Common Stock (GlobeNewswire)
Dec-12-21 08:00PM	Avenue Therapeutics Prices $2.0 Million Underwritten Public Offering of Common Stock (GlobeNewswire)
Nov-29-21 08:00AM	Avenue Therapeutics Announces FDA Advisory Committee Meeting to Review IV Tramadol NDA Tentatively Scheduled for February 15, 2022 (GlobeNewswire) +53.15%
Nov-17-21 09:30AM	Avenue Therapeutics Announces Exercise and Closing of Underwriters Over-Allotment Option (GlobeNewswire)
Nov-12-21 10:40AM	Aegis Capital Corp. acted as Sole Bookrunner on a $2.6 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI) (ACCESSWIRE)
09:20AM	Avenue Therapeutics Announces Closing of Public Offering of Common Stock (GlobeNewswire)
Nov-09-21 09:30PM	Avenue Therapeutics Prices $2.6 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -8.14%
Oct-25-21 07:00AM	Avenue Therapeutics Receives Interim Response to its Formal Dispute Resolution Request from U.S. Food and Drug Administration Office of New Drugs (GlobeNewswire) +25.40%
Aug-26-21 11:04AM	Amneal (AMRX) Parkinson's Candidate Successful in Pivotal Study (Zacks)
Jun-21-21 08:04AM	Mondays Pre-Market: Heres What You Need to Know Before the Market Opens (TipRanks)
Jun-14-21 08:42AM	Mondays Pre-Market: Heres What You Need to Know Before the Market Opens (TipRanks) -28.27%
07:44AM	CORRECTED-U.S. FDA declines to approve Avenue's painkiller again, shares drop (Reuters)
07:00AM	Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol (GlobeNewswire)
Apr-26-21 08:09AM	BioRad (BIO) to Report Q1 Earnings: What's in the Cards? (Zacks)
Apr-23-21 11:36PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI (GlobeNewswire)
09:43AM	What's in Store for Perrigo (PRGO) This Earnings Season? (Zacks)
08:41AM	ResMed (RMD) to Report Q3 Earnings: What's in the Offing? (Zacks)
Apr-22-21 10:59AM	Integra (IART) to Report Q1 Earnings: What's in the Offing? (Zacks)
Apr-21-21 10:34PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI (Newsfile) +16.37%
09:38AM	VITUS to Hurt Chemed (CHE) Q1 Earnings, Roto-Rooter to Aid (Zacks)
Apr-19-21 10:09PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI (PR Newswire)
06:26AM	Avenue Therapeutics (ATXI) Sees Hammer Chart Pattern: Time to Buy? (Zacks)
Apr-16-21 11:25PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI (ACCESSWIRE)
Apr-14-21 10:34PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avenue Therapeutics, Inc. - ATXI (GlobeNewswire) -11.99%
Apr-13-21 11:30PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI (PR Newswire) -23.77%
03:09PM	Why Fortress Biotech Stock Is Sinking Today (Motley Fool)
02:30PM	Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Avenue Therapeutics, Inc. (ATXI) Investigation (ACCESSWIRE)
09:33AM	JAZZ's Xywav sNDA for Hypersomnia Gets FDA Priority Review (Zacks)
06:30AM	Avenue Therapeutics Announces that the FDA is Still Reviewing Its NDA Resubmission for IV Tramadol (GlobeNewswire)
Apr-12-21 01:36AM	Is Avenue Therapeutics (NASDAQ:ATXI) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jan-11-21 11:32PM	How Much Of Avenue Therapeutics, Inc. (NASDAQ:ATXI) Do Institutions Own? (Simply Wall St.)
Jan-06-21 09:23AM	Is Avenue Therapeutics (ATXI) Stock a Buy For 2021? (Insider Monkey)
Dec-18-20 08:00AM	Avenue Therapeutics Announces Publication of Tramadol Non-Medical Use in Four European Countries: A Comparative Analysis (GlobeNewswire) +15.41%
08:00AM	Avenue Therapeutics Announces Publication of Real-World Data on Nonmedical Use of Tramadol in ASI-MV Network (GlobeNewswire)
Dec-17-20 04:27PM	Why Fortress Biotech Stock Jumped Today (Motley Fool) +47.70%
07:00AM	Avenue Therapeutics Provides Regulatory Update for IV Tramadol (GlobeNewswire)
Nov-13-20 05:28AM	Read This Before Selling Avenue Therapeutics, Inc. (NASDAQ:ATXI) Shares (Simply Wall St.)
Oct-28-20 07:45PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI (ACCESSWIRE)
Oct-23-20 10:00PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI (ACCESSWIRE)
Oct-14-20 08:58PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI (PR Newswire)
10:10AM	Biotech Stock Roundup: REGN, GILD's Coronavirus News & Other Pipeline Updates (Zacks)
Oct-13-20 01:29PM	Avenue Therapeutics' Pain Drug Gets Complete Response Letter (Zacks) -14.57%
Oct-12-20 01:35PM	Avenue Therapeutics Sinks As FDA Rejects Opioid Pain Drug On Safety Concerns (Benzinga) -58.97%
12:45PM	Why Fortress Biotech Stock Is Plunging Today (Motley Fool)
10:47AM	Why Fortress Biotech's Stock Is Trading Lower Today (Benzinga)
06:30AM	Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol (GlobeNewswire)
Sep-09-20 08:00AM	Avenue Therapeutics Announces Publication of a Review of IV Tramadol (GlobeNewswire)
Aug-17-20 10:33AM	Avenue Therapeutics (ATXI) Misses Earnings Estimates in Q2 (Zacks)
Aug-14-20 07:30AM	Avenue Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-04-20 12:53PM	What's in Store for Avenue Therapeutics (ATXI) in Q2 Earnings? (Zacks)
Jul-28-20 05:50PM	Avenue Therapeutics, Inc. (ATXI) Dips More Than Broader Markets: What You Should Know (Zacks)

Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, a potential alternative that could reduce the use of conventional opioids for patients suffering from acute pain. The company was founded on February 9, 2015 and is headquartered in Bay Harbor Islands, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Davidow Robert L	10% Owner	Dec 11 '23	Sale	0.14	353,000	49,600	22,000	Dec 13 04:02 PM
Davidow Robert L	10% Owner	Dec 11 '23	Sale	0.14	264,000	36,960	681,000	Dec 13 04:02 PM
Fortress Biotech, Inc.	10% Owner	Sep 08 '23	Buy	0.72	418,410	301,255	1,032,390	Sep 12 09:02 AM
ROSENWALD LINDSAY A MD	Director	Sep 08 '23	Buy	0.72	348,675	251,046	354,318	Sep 12 09:03 AM

Open in Screener

MBIO

Mustang Bio Inc

May 03 • 04:00PM ET

0.3178

Dollar change +0.0248
Percentage change 8.46	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC FESM

Index	-	P/E	-	EPS (ttm)	-6.23	Insider Own	28.08%	Shs Outstand	8.37M	Perf Week	0.54%
Market Cap	3.61M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	8.17M	Perf Month	-59.52%
Income	-51.60M	PEG	-	EPS next Q	-	Inst Own	9.52%	Short Float	1.67%	Perf Quarter	-77.14%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-65.99%	Short Ratio	0.57	Perf Half Y	-79.76%
Book/sh	0.01	P/B	23.82	EPS next Y	-	ROA	-93.68%	Short Interest	0.14M	Perf Year	-92.17%
Cash/sh	0.55	P/C	0.58	EPS next 5Y	-	ROE	-222.44%	52W Range	0.22 - 8.17	Perf YTD	-76.46%
Dividend Est.	-	P/FCF	-	EPS past 5Y	18.87%	ROI	-2456.07%	52W High	-96.11%	Beta	1.74
Dividend TTM	-	Quick Ratio	0.74	Sales past 5Y	0.00%	Gross Margin	-	52W Low	44.45%	ATR (14)	0.07
Dividend Ex-Date	-	Current Ratio	0.74	EPS Y/Y TTM	44.66%	Oper. Margin	0.00%	RSI (14)	30.34	Volatility	19.40% 18.85%
Employees	80	Debt/Eq	20.83	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	10.00
Option/Short	No / Yes	LT Debt/Eq	16.50	EPS Q/Q	65.94%	Payout	-	Rel Volume	0.69	Prev Close	0.29
Sales Surprise	-	EPS Surprise	54.39%	Sales Q/Q	-	Earnings	Mar 11 AMC	Avg Volume	239.48K	Price	0.32
SMA20	-23.27%	SMA50	-62.35%	SMA200	-82.93%	Trades		Volume	164,817	Change	8.46%

Date	Action	Analyst	Rating Change	Price Target Change
May-18-21	Initiated	BTIG Research	Buy	$11
Oct-02-20	Initiated	B. Riley FBR	Buy	$9
Nov-20-19	Initiated	Cantor Fitzgerald	Overweight	$7
Aug-13-19	Initiated	H.C. Wainwright	Buy	$7
Jun-21-19	Initiated	Cantor Fitzgerald	Overweight	$7
Dec-21-17	Initiated	Oppenheimer	Outperform	$18

May-02-24 04:01PM	Mustang Bio Announces Closing of $4 Million Public Offering (GlobeNewswire) +12.65%
Apr-30-24 06:03AM	Mustang Bio Prices Public Offering of 16.9 Million Shares, Accompanying Warrants (MT Newswires)
Apr-29-24 08:00PM	Mustang Bio Announces Pricing of $4 Million Public Offering (GlobeNewswire) -25.02%
Mar-28-24 04:05PM	Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire) +10.64%
09:00AM	Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases (GlobeNewswire)
04:05PM	Loading…
Mar-11-24 04:05PM	Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire) -7.20%
Mar-07-24 07:30AM	Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13R 2-targeted CAR T-Cells in High-Grade Glioma (GlobeNewswire) +5.30%
Jan-11-24 08:30AM	Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference (GlobeNewswire)
Dec-11-23 08:30AM	Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) -7.14%
Nov-14-23 04:05PM	Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-02-23 09:28AM	Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-30-23 02:15PM	Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Oct-26-23 12:30PM	Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -10.19%
09:00AM	Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13R 2 targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma (GlobeNewswire)
Sep-07-23 08:15AM	Mustang Bio to Participate in Upcoming September 2023 Investor Conferences (GlobeNewswire)
08:00AM	Loading…
Aug-16-23 08:00AM	Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy (GlobeNewswire)
Aug-14-23 04:05PM	Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire) -11.04%
04:01PM	Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-03-23 08:00AM	Mustang Bio to Participate in Two August 2023 Investor Conferences (GlobeNewswire)
Jul-31-23 08:30AM	Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences (GlobeNewswire) +8.56%
Jul-06-23 08:00AM	Mustang Bio Announces Participation in Upcoming Scientific Meetings (GlobeNewswire) -5.78%
Jun-15-23 04:01PM	Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy (GlobeNewswire) +10.76%
Jun-13-23 01:49PM	Mustang (MBIO) Up 9% on Rare Blood Cancer Study's Upbeat Data (Zacks) -6.29%
Jun-12-23 09:55AM	Wall Street Analysts Think Mustang Bio, Inc. (MBIO) Could Surge 331.15%: Read This Before Placing a Bet (Zacks) +9.16%
08:00AM	Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy (GlobeNewswire)
May-26-23 09:55AM	Wall Street Analysts Believe Mustang Bio, Inc. (MBIO) Could Rally 711.55%: Here's is How to Trade (Zacks)
May-18-23 08:03AM	Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates (GlobeNewswire)
May-15-23 04:01PM	Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire) -6.65%
May-12-23 04:05PM	Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-11-23 04:03PM	Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy (GlobeNewswire)
12:15PM	Loading…
Apr-03-23 12:15PM	Mustang Bio Announces Reverse Stock Split (GlobeNewswire) -11.32%
Mar-30-23 04:10PM	Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire) +6.30%
Mar-29-23 04:15PM	Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-28-23 08:30AM	Mustang Bio to Participate in Cantors The Future of Oncology Virtual Symposium (GlobeNewswire)
Jan-17-23 08:15AM	Mustang Bio to Participate in the B. Riley Securities 3rd Annual Oncology Conference (GlobeNewswire) +9.19%
Dec-19-22 08:30AM	Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones (GlobeNewswire) -10.09%
Nov-14-22 04:05PM	Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Oct-27-22 08:00AM	Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia (GlobeNewswire) +5.17%
Oct-06-22 08:30AM	Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (GlobeNewswire)
Sep-08-22 08:00AM	Mustang Bio to Participate in Upcoming September 2022 Investor Conferences (GlobeNewswire)
Sep-02-22 09:55AM	Here's Why Mustang Bio, Inc. (MBIO) Looks Ripe for Bottom Fishing (Zacks)
Aug-11-22 04:05PM	Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Jul-27-22 08:00AM	Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency (GlobeNewswire)
Jul-17-22 08:21AM	Mustang Bio, Inc. (NASDAQ:MBIO) insider upped their holding by 9.9% earlier this year (Simply Wall St.)
Jun-22-22 08:00AM	Mustang Bio Announces Orphan Drug Designation Granted to MB-106, a CD20-targeted, Autologous CAR T Cell Therapy for the Treatment of Waldenstrom Macroglobulinemia (GlobeNewswire) +12.57%
Jun-13-22 08:00AM	Mustang Bio Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy (GlobeNewswire)
May-19-22 03:23PM	Mustang Bio Posts Encouraging Interim Data From Gene Therapy Trial In Immunodeficiency (Benzinga)
08:45AM	Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107 (GlobeNewswire)
May-12-22 04:05PM	Mustang Bio Reports First Quarter 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
10:38AM	Mustang Bio Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid Congress (GlobeNewswire)
May-03-22 08:00AM	Mustang Bio Announces Data on Treatment with Lentiviral Viral Vector Gene Therapy for X-Linked Severe Combined Immunodeficiency Selected for Oral Presentation at American Society of Gene & Cell Therapy 25th Annual Meeting (GlobeNewswire) -5.35%
Apr-25-22 08:00AM	Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106, CD20-Targeted CAR T Therapy, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (GlobeNewswire)
Apr-21-22 08:30AM	Mustang Bio Announces Upcoming MB-106 CD20-Targeted CAR T Data Presentations (GlobeNewswire) -5.16%
Apr-13-22 10:00AM	Mustang Bio Announces a Phase 1 Clinical Trial Combining MB-101 (IL13R2targeted CAR T cell therapy) and MB-108 (C134 oncolytic virus) for the Treatment of Glioblastoma (GlobeNewswire)
Apr-04-22 08:00AM	Mustang Bio to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities (GlobeNewswire) +8.65%
Apr-01-22 08:30AM	Fortress Biotech Announces Virtual Two-Day R&D Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022 (GlobeNewswire)
Mar-23-22 04:05PM	Mustang Bio Reports Full-Year 2021 Financial Results and Recent Corporate Highlights (GlobeNewswire) -9.71%
Mar-10-22 08:30AM	Mustang Bio to Participate in Three March 2022 Investor Conferences (GlobeNewswire) -6.41%
Mar-09-22 08:00AM	Mustang Bio Announces City of Hope, University of Alabama at Birmingham and Nationwide Childrens Hospital Abstract Accepted for Late-Breaker Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022 (GlobeNewswire) +14.18%
Mar-08-22 09:00AM	Mustang Bio Completes a $75 Million Debt Financing with Runway Growth Capital (GlobeNewswire)
Feb-15-22 07:30AM	Mustang Bio Announces City of Hope MB-105 Prostate Stem Cell Antigen CAR T Data Selected for Presentation at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium (GlobeNewswire) +6.93%
Feb-08-22 08:30AM	Mustang Bio Selected as a Bronze Winner in Eighteenth Annual Team Massachusetts Economic Impact Awards (GlobeNewswire)
Feb-07-22 09:11AM	One Mustang Bio, Inc. (NASDAQ:MBIO) insider upped their stake by 25% in the previous year (Simply Wall St.)
Jan-25-22 07:10AM	FDA Holds Mustang Bio's Gene Therapy IND For Compromised Immune System Disorder (Benzinga) -6.15%
Jan-24-22 05:00PM	Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency (XSCID) in Previously Transplanted Patients (GlobeNewswire)
Jan-07-22 02:05PM	Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (GlobeNewswire)
Jan-05-22 08:30AM	Mustang Bio to Participate in Three January 2022 Virtual Investor Conferences (GlobeNewswire) -5.26%
Dec-16-21 08:30AM	Mustang Bio Added to the NASDAQ Biotechnology Index (GlobeNewswire)
Dec-13-21 09:00AM	Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (GlobeNewswire) -11.59%
Dec-09-21 08:30AM	Mustang Bio to Host Key Opinion Leader Webinar on MB-106, a Potential Treatment for B-Cell Non Hodgkin Lymphomas and Chronic Lymphocytic Leukemia (GlobeNewswire)
Dec-06-21 07:30AM	Here's Why We're Watching Mustang Bio's (NASDAQ:MBIO) Cash Burn Situation (Simply Wall St.)
Nov-12-21 08:05AM	Mustang Bio Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-10-21 08:00AM	Mustang Bio Announces Exclusive Worldwide License Agreement with Leiden University Medical Centre for Clinical-Stage Lentiviral Gene Therapy with Curative Potential for RAG1 Severe Combined Immunodeficiency (GlobeNewswire)
Nov-09-21 09:02AM	3 Penny Stocks Insiders Are Buying (Benzinga) +6.69%
Nov-04-21 09:24AM	Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-01-21 10:19AM	Mustang Bio Secures $2M NIH Grant For CAR T Cell Therapy Development (Benzinga) +6.25%
08:30AM	Mustang Bio Awarded NIH Grant For MB-106 CD20-Targeted CAR T Cell Therapy for Treatment of B-cell non-Hodgkin Lymphomas (GlobeNewswire)
Oct-06-21 10:28AM	Here's What Mustang Bio, Inc.'s (NASDAQ:MBIO) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Oct-04-21 09:57AM	Mustang Bio, Inc. (MBIO): Hedge Funds In Wait-and-See Mode (Insider Monkey) -6.82%
Sep-30-21 08:30AM	Mustang Bio to Participate in Chardans Virtual 5th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-28-21 08:30AM	Mustang Bio Announces MB-101 (IL13R2targeted CAR T cells) Scientific Presentations at Upcoming Virtual Conferences (GlobeNewswire)
Sep-24-21 06:10AM	Mustang Bio (MBIO) Sees Hammer Chart Pattern: Time to Buy? (Zacks)
Sep-09-21 08:30AM	Mustang Bio to Participate in Three September 2021 Investor Conferences (GlobeNewswire)
Aug-16-21 04:01PM	Mustang Bio Reports Second Quarter 2021 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-13-21 10:03AM	Mustang Bio, Mayo Clinic Join Forces On New CAR T Tech In Tumor Settings (Benzinga)
Aug-12-21 04:45PM	Mustang Bio Collaborates with Mayo Clinic on Novel CAR T Technology (GlobeNewswire)
Aug-07-21 03:50AM	Trade Alert: The President Of Mustang Bio, Inc. (NASDAQ:MBIO), Manuel Litchman, Has Just Spent US$251k Buying 9.9% More Shares (Simply Wall St.)
Aug-02-21 10:31AM	Mustang Bio's Gene Therapy For Genetic Immunodeficiency Receives European PRIME Tag (Benzinga)
08:00AM	Mustang Bio Receives European Medicines Agency PRIME Designation for MB-107 to Treat X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants (GlobeNewswire)
Jul-14-21 09:11AM	15 Best Penny Stocks to Buy Now (Insider Monkey)
Jun-17-21 08:00AM	Mustang Bio Awarded Massachusetts Life Sciences Center Tax Incentive (GlobeNewswire)
Jun-16-21 08:30AM	Mustang Bio to Present at the Raymond James Human Health Innovation Conference (GlobeNewswire)
Jun-15-21 04:32AM	Here's Why We're Not Too Worried About Mustang Bio's (NASDAQ:MBIO) Cash Burn Situation (Simply Wall St.)
Jun-11-21 07:28AM	Mustang Bio's CAR T Cell Therapy Achieves 93% ORR, 67% CR In Mid-Stage Leukemia Trial (Benzinga)
06:30AM	Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia (GlobeNewswire)
Jun-07-21 08:00AM	Mustang Bio to Host Key Opinion Leader Webinar on MB-106 CD20-Targeted CAR T for the Treatment of High-Risk B-Cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia (GlobeNewswire)
May-18-21 04:03PM	Why Mustang Bio Stock Galloped Higher Today (Motley Fool) +10.84%
09:26AM	BTIG Sees 260% Upside In Mustang Bio With PT of $11; Early-Stage MB-101 Starts Dosing Brain Tumor Patients (Benzinga)
08:00AM	Mustang Bio and City of Hope Announce First Patient Dosed in Phase 1 Clinical Trial of MB-101 (IL13R2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors (GlobeNewswire)
May-14-21 04:30PM	Mustang Bio Reports First Quarter 2021 Financial Results and Recent Corporate Highlights (GlobeNewswire)

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline includes CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors, and gene therapies for rare genetic disorders. The company was founded on March 13, 2015 and is headquartered in Worcester, MA.

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

DERM

Journey Medical Corp

FBIO

Fortress Biotech Inc

ATXI

Avenue Therapeutics Inc

MBIO

Mustang Bio Inc

Upgrade your FINVIZ experience